NO20045232L - Fremgangsmater ved okning av den terapeutiske respons overfor elektrokonvulsiv terapi - Google Patents

Fremgangsmater ved okning av den terapeutiske respons overfor elektrokonvulsiv terapi

Info

Publication number
NO20045232L
NO20045232L NO20045232A NO20045232A NO20045232L NO 20045232 L NO20045232 L NO 20045232L NO 20045232 A NO20045232 A NO 20045232A NO 20045232 A NO20045232 A NO 20045232A NO 20045232 L NO20045232 L NO 20045232L
Authority
NO
Norway
Prior art keywords
increasing
methods
therapeutic response
electroconvulsive therapy
electroconvulsive
Prior art date
Application number
NO20045232A
Other languages
English (en)
Other versions
NO335006B1 (no
Inventor
Alan F Schatzberg
Joseph K Belanoff
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Publication of NO20045232L publication Critical patent/NO20045232L/no
Publication of NO335006B1 publication Critical patent/NO335006B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Electrotherapy Devices (AREA)

Abstract

Oppfinnelsen angår generelt området psykiatri. Spesielt angår foreliggende oppfinnelse den oppdagelse at midler som inhiberer bindingen av kortisol til glukokortikoid-resep5 toren kan bli brukt i fremgangsmåter for å øke den terapeutiske respons overfor elektrokonvulsiv terapi ("ECT").
NO20045232A 2002-04-29 2004-11-29 Anvendelse av glukokortikoidreseptor-antagonist for fremstilling av medikament til behandling innen elektrokonvulsiv terapi NO335006B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37681402P 2002-04-29 2002-04-29
US10/411,503 US7326697B2 (en) 2002-04-29 2003-04-08 Methods for increasing the therapeutic response to electroconvulsive therapy
PCT/US2003/013498 WO2003092790A2 (en) 2002-04-29 2003-04-28 Methods for increasing the therapeutic response to electroconvulsive therapy ('ect')

Publications (2)

Publication Number Publication Date
NO20045232L true NO20045232L (no) 2005-01-26
NO335006B1 NO335006B1 (no) 2014-08-25

Family

ID=29406770

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20045232A NO335006B1 (no) 2002-04-29 2004-11-29 Anvendelse av glukokortikoidreseptor-antagonist for fremstilling av medikament til behandling innen elektrokonvulsiv terapi

Country Status (16)

Country Link
US (1) US7326697B2 (no)
EP (1) EP1499321B1 (no)
JP (2) JP2005526843A (no)
KR (1) KR100970834B1 (no)
CN (1) CN100438875C (no)
AT (1) ATE529116T1 (no)
AU (1) AU2003228783B2 (no)
CA (1) CA2483855C (no)
ES (1) ES2375356T3 (no)
HK (1) HK1068783A1 (no)
IL (2) IL164793A0 (no)
MX (1) MXPA04010705A (no)
NO (1) NO335006B1 (no)
NZ (1) NZ536248A (no)
PT (1) PT1499321E (no)
WO (1) WO2003092790A2 (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040226556A1 (en) * 2003-05-13 2004-11-18 Deem Mark E. Apparatus for treating asthma using neurotoxin
US8097606B2 (en) * 2003-07-23 2012-01-17 Corcept Therapeutics, Inc. Antiglucocorticoids for the treatment of catatonia
US8041428B2 (en) 2006-02-10 2011-10-18 Electrocore Llc Electrical stimulation treatment of hypotension
US8812112B2 (en) * 2005-11-10 2014-08-19 ElectroCore, LLC Electrical treatment of bronchial constriction
US9037247B2 (en) 2005-11-10 2015-05-19 ElectroCore, LLC Non-invasive treatment of bronchial constriction
WO2007058780A2 (en) * 2005-11-10 2007-05-24 Electrocore, Inc. Electrical stimulation treatment of bronchial constriction
US20110125203A1 (en) * 2009-03-20 2011-05-26 ElectroCore, LLC. Magnetic Stimulation Devices and Methods of Therapy
WO2007094828A2 (en) 2006-02-10 2007-08-23 Electrocore, Inc. Electrical stimulation treatment of hypotension
AU2006337679A1 (en) * 2006-02-10 2007-08-16 Electrocore, Inc. Methods and apparatus for treating anaphylaxis using electrical modulation
US20100241188A1 (en) * 2009-03-20 2010-09-23 Electrocore, Inc. Percutaneous Electrical Treatment Of Tissue
EP1987814A1 (en) * 2007-04-30 2008-11-05 Exelgyn Mifepristone pharmaceutical compositions and their methods of preparation
US8483831B1 (en) 2008-02-15 2013-07-09 Holaira, Inc. System and method for bronchial dilation
CN102014779B (zh) 2008-05-09 2014-10-22 赫莱拉公司 用于治疗支气管树的系统、组件和方法
CN107049479B (zh) * 2009-10-27 2020-10-16 努瓦拉公司 具有可冷却的能量发射组件的递送装置
EP4111995A1 (en) 2009-11-11 2023-01-04 Nuvaira, Inc. Device for treating tissue and controlling stenosis
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
US20120245552A1 (en) * 2011-03-23 2012-09-27 Pop Test Cortisol Llc Combination Therapy
US10500216B2 (en) 2011-11-18 2019-12-10 Corcept Therapeutics, Inc. Optimizing mifepristone absorption
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation
US9943526B2 (en) 2015-04-21 2018-04-17 Corcept Therapeutics, Inc. Optimizing mifepristone levels for cushing's patients

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4296206A (en) 1980-04-30 1981-10-20 United States Of America Irreversible anti-glucocorticoids
ZA8231B (en) 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
FR2598421B1 (fr) 1986-05-06 1988-08-19 Roussel Uclaf Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
US4873981A (en) 1988-10-14 1989-10-17 Somatics, Inc. Electroconvulsive therapy apparatus and method for automatic monitoring of patient seizures
FR2757400B1 (fr) * 1996-12-19 1999-12-17 Hoechst Marion Roussel Inc Application des composes antiglucocorticoides dans le traitement des psychoses ou des comportements addictifs
EP1023074B1 (en) * 1997-10-06 2006-07-12 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating psychosis associated with glucocorticoid related dysfunction
WO1999059596A1 (en) 1998-05-15 1999-11-25 The Board Of Trustees Of Leland Stanford Junior University Glucocorticoid receptor antagonists for the treatment of dementia
WO2004054467A1 (en) * 2002-12-18 2004-07-01 Koninklijke Philips Electronics N.V. System for removably joining a driven member to a driven member with workpiece

Also Published As

Publication number Publication date
CN100438875C (zh) 2008-12-03
US7326697B2 (en) 2008-02-05
MXPA04010705A (es) 2005-02-17
CA2483855A1 (en) 2003-11-13
AU2003228783C1 (en) 2003-11-17
NZ536248A (en) 2007-03-30
CN1658883A (zh) 2005-08-24
JP2005526843A (ja) 2005-09-08
NO335006B1 (no) 2014-08-25
KR100970834B1 (ko) 2010-07-16
AU2003228783B2 (en) 2006-11-16
JP2011116771A (ja) 2011-06-16
CA2483855C (en) 2012-01-10
IL164793A (en) 2012-02-29
US20040029849A1 (en) 2004-02-12
ES2375356T3 (es) 2012-02-29
EP1499321A2 (en) 2005-01-26
EP1499321B1 (en) 2011-10-19
KR20040105247A (ko) 2004-12-14
WO2003092790A2 (en) 2003-11-13
EP1499321A4 (en) 2008-09-03
IL164793A0 (en) 2005-12-18
ATE529116T1 (de) 2011-11-15
PT1499321E (pt) 2012-02-01
HK1068783A1 (en) 2005-05-06
AU2003228783A1 (en) 2003-11-17
WO2003092790A3 (en) 2003-12-11

Similar Documents

Publication Publication Date Title
HK1068783A1 (en) Methods for increasing the therapeutic response to electroconvulsive therapy ("ect")
FR16C0028I2 (fr) Vecteurs viraux et utilisation de ces derniers dans des methodes therapeutiques
MY158162A (en) 5-membered heterocycle-based p38 kinase inhibitors
ATE256672T1 (de) 4,5-diaryl-3(2h)-furanon derivate als cyclooxygenase-2 inhibitoren
DE602004024572D1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
MX2007000606A (es) Arilidenos para el tratamiento de enfermedades mediadas por receptor alfa relacionado con estrogeno.
ATE509019T1 (de) Benzodiazepinspirohydantoine als cgrp- rezeptorantagonisten
BRPI0409701A (pt) ligantes de receptores de canabinóides e seus usos
NO20055516L (no) Kannabinoidreceptorligander og anvendelser derav
TNSN07161A1 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
BRPI0410905A (pt) inibidores de p-38
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
NO20085373L (no) P38 inhibitorer, deres fremstilling og anvendelse
ATE390917T1 (de) Prävention und behandlung von skeletterkrankungen mit ep2 subtyp selektiven prostaglandin e2 agonisten
NO20073369L (no) Modulatorer av muskarinreseptorer
DE602006005254D1 (de) Neue chinolinverbindungen, die dazu in der lage sind, sich an den cb2-rezeptor zu binden
NO995657D0 (no) Kombinasjonsterapi for endring av human seksuell respons
GB0326633D0 (en) Therapeutic agents
ATE247130T1 (de) Inhibitoren für den urokinaserezeptor
WO2004087690A3 (en) Benzimidazole derivatives and their use for modulating the gaba-a receptor complex
DE602004019541D1 (de) Cycloalkyläbü kondensierte indole
TR200000916T2 (tr) İkameli piperidin türevleri.
TW200510390A (en) Benzimidazole derivatives and their use for modulating the GABAA receptor complex
TNSN05307A1 (en) 5-membered heterocycle-based p38 kinase inhibitors

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees